Attenuation of Eph receptor kinase activation in cancer cells by coexpressed ephrin ligands

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Falivelli, Giulia ^a,d   Lisabeth, Erika Mathes ^a   De La Torre, Elena Rubio ^a   Perez Tenorio, Gizeh ^a,e   Tosato, Giovanna ^b   Salvucci, Ombretta ^b   Pasquale, Elena B ^a,c  

^a BURNHAM INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN; EPHRIN A2; EPHRIN A3; EPHRIN B2; EPHRIN B4; EPHRIN RECEPTOR TYROSINE KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CIS TRANS ISOMERISM; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIGAND BINDING; LUNG CANCER; LUNG CARCINOGENESIS; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; EPHRINS; HUMANS; IMMUNOPRECIPITATION; PROTEIN BINDING; RECEPTOR, EPHA2; RECEPTOR, EPHA3; RECEPTOR, EPHB4; RECEPTORS, EPH FAMILY;

EID: 84896715497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081445     Document Type: Article

References (51)

1. Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180. doi:10.1038/nrc2806. PubMed: 20179713.
2. Lisabeth EM, Falivelli G, Pasquale EB (2013) Eph receptor signaling and ephrins. Cold Spring Harb Perspect. Biol (in press).
3. Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6: 462-475. doi:10.1038/nrm1662. PubMed: 15928710.
4. Bartley TD, Hunt RW, Welcher AA, Boyle WJ, Parker VP et al. (1994) B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 368: 558-560. doi:10.1038/368558a0. PubMed: 8139691. (Pubitemid 24118774)
5. Hattori M, Osterfield M, Flanagan JG (2000) Regulated cleavage of a contact-mediated axon repellent. Science 289: 1360-1365. doi:10.1126/science. 289.5483.1360. PubMed: 10958785. (Pubitemid 30656055)
6. Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J et al. (2012) EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol 32: 3253-3264. doi:10.1128/MCB.06791-11. PubMed: 22688511.
7. Alford SC, Bazowski J, Lorimer H, Elowe S, Howard PL (2007) Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. Exp Cell Res 313: 4170-4179. doi: 10.1016/j.yexcr.2007.07.019. PubMed: 17707797. (Pubitemid 350087045)
8. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T et al. (2001) Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 3: 527-530. doi:10.1038/35074604. PubMed: 11331884. (Pubitemid 32422092)
9. Yang NY, Fernandez C, Richter M, Xiao Z, Valencia F et al. (2011) Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal 23: 201-212. doi:10.1016/j.cellsig.2010.09.004. PubMed: 20837138.
10. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E et al. (2002) beta-Catenin and TCF Mediate Cell Positioning in the Intestinal Epithelium by Controlling the Expression of EphB/EphrinB. Cell 111: 251-263. doi:10.1016/S0092-8674(02)01015-2. PubMed: 12408869. (Pubitemid 35292445)
11. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J et al. (2005) A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8: 111-118. doi:10.1016/j.ccr.2005.07.005. PubMed: 16098464. (Pubitemid 41132740)
12. Noren NK, Foos G, Hauser CA, Pasquale EB (2006) The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8: 815-825. doi:10.1038/ncb1438. PubMed: 16862147. (Pubitemid 44151584)
13. Ji XD, Li G, Feng YX, Zhao JS, Li JJ et al. (2011) EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res 71: 1156-1166. doi:10.1158/0008-5472.CAN-10- 0717. PubMed: 21266352.
14. Lisabeth EM, Fernandez C, Pasquale EB (2012) Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry 51: 1464-1475. doi: 10.1021/bi2014079. PubMed: 22242939.
15. Zhuang G, Song W, Amato K, Hwang Y, Lee K et al. (2012) Effects of cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer Inst 104: 1182-1197. PubMed: 22829656.
16. Zantek ND, Azimi M, Fedor-Chaiken M, Wang BC, Brackenbury R et al. (1999) E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth and Differentiation 10: 629-638. PubMed: 10511313. (Pubitemid 29455727)
17. Yin Y, Yamashita Y, Noda H, Okafuji T, Go MJ et al. (2004) EphA receptor tyrosine kinases interact with co-expressed ephrin-A ligands in cis. Neurosci Res 48: 285-296. doi:10.1016/j.neures.2003.11.009. PubMed: 15154674. (Pubitemid 38220946)
18. Carvalho RF, Beutler M, Marler KJ, Knöll B, Becker-Barroso E et al. (2006) Silencing of EphA3 through a cis interaction with ephrinA5. Nat Neurosci 9: 322-330. doi:10.1038/nn1655. PubMed: 16491080. (Pubitemid 43290961)
19. Hornberger MR, Dütting D, Ciossek T, Yamada T, Handwerker C et al. (1999) Modulation of EphA receptor function by coexpressed ephrinA ligands on retinal ganglion cell axons. Neuron 22: 731-742. doi: 10.1016/S0896-6273(00) 80732-1. PubMed: 10230793. (Pubitemid 29203496)
20. Kao TJ, Kania A (2011) Ephrin-mediated cis-attenuation of Eph receptor signaling is essential for spinal motor axon guidance. Neuron 71: 76-91. doi:10.1016/j.neuron.2011.05.031. PubMed: 21745639.
21. Antion MD, Christie LA, Bond AM, Dalva MB, Contractor A (2010) Ephrin-B3 regulates glutamate receptor signaling at hippocampal synapses. Mol Cell Neurosci 45: 378-388
22. Marquardt T, Shirasaki R, Ghosh S, Andrews SE, Carter N et al. (2005) Coexpressed EphA Receptors and Ephrin-A Ligands Mediate Opposing Actions on Growth Cone Navigation from Distinct Membrane Domains. Cell 121: 127-139. doi:10.1016/j.cell.2005.01.020. PubMed: 15820684.
23. Seiradake E, Harlos K, Sutton G, Aricescu AR, Jones EY (2010) An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat Struct Mol Biol 17: 398-402. doi:10.1038/nsmb.1782. PubMed: 20228801.
24. Himanen JP, Rajashankar KR, Lackmann M, Cowan CA, Henkemeyer M et al. (2001) Crystal structure of an Eph receptor-ephrin complex. Nature 414: 933-938. doi:10.1038/414933a. PubMed: 11780069. (Pubitemid 34024747)
25. Flanagan JG, Vanderhaeghen P (1998) The ephrins and Eph receptors in neural development. Annu Rev Neurosci 21: 309-345. doi:10.1146/annurev.neuro.21. 1.309. PubMed: 9530499. (Pubitemid 28150666)
26. Wykosky J, Debinski W (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6: 1795-1806. doi:10.1158/1541-7786.MCR-08-0244. PubMed: 19074825.
27. Tandon M, Vemula SV, Mittal SK (2011) Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 15: 31-51. doi:10.1517/14728222.2011.538682. PubMed: 21142802.
28. Biao-Xue R, Xi-Guang C, Shuan-Ying Y, Wei L, Zong-Juan M (2011) EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors. Curr Cancer Drug Targets 11: 1082-1097. doi: 10.2174/156800911798073050. PubMed: 21933105.
29. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075. doi:10.1038/nature07423. PubMed: 18948947.
30. Noren NK, Pasquale EB (2007) Paradoxes of the EphB4 receptor in cancer. Cancer Res 67: 3994-3997. doi: 10.1158/0008-5472.CAN-07-0525. PubMed: 17483308. (Pubitemid 46815041)
31. Alford S, Watson-Hurthig A, Scott N, Carette A, Lorimer H et al. (2010) Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells. Cancer Cell Int 10: 41. doi:10.1186/1475-2867-10-41. PubMed: 20979646.
32. Yaron A, Sprinzak D (2012) The cis side of juxtacrine signaling: a new role in the development of the nervous system. Trends Neurosci 35: 230-239. doi:10.1016/j.tins.2011.12.003. PubMed: 22222351.
33. Nitschke L (2009) CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev 230: 128-143. doi:10.1111/j.1600-065X.2009. 00801.x. PubMed: 19594633.
34. Ware CF, Sedý JR (2011) TNF Superfamily Networks: bidirectional and interference pathways of the herpesvirus entry mediator (TNFSF14). Curr Opin Immunol 23: 627-631. doi:10.1016/j.coi.2011.08.008. PubMed: 21920726.
35. Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38-52. doi:10.1016/j.cell.2008.03.011. PubMed: 18394988.
36. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J et al. (2013) EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme. Cancer Cell 23: 238-248. doi:10.1016/j.ccr.2013.01.007. PubMed: 23410976.
37. Xi HQ, Zhao P (2011) Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 64: 498-503. doi:10.1136/jcp.2010.087213. PubMed: 21415057.
38. Keane N, Freeman C, Swords R, Giles FJ (2012) EPHA3 as a novel therapeutic target in the hematological malignancies. Expert. Rev Hematol 5: 325-340.
39. Xi HQ, Wu XS, Wei B, Chen L (2012) Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival. J Gastroenterol 47: 785-794. doi:10.1007/s00535-012-0549-4. PubMed: 22350700.
40. Clevers H, Batlle E (2006) EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res 66: 2-5. doi: 10.1158/0008-5472.CAN-05-3849. PubMed: 16397205. (Pubitemid 43165998)
41. Chen J, Zhuang G, Frieden L, Debinski W (2008) Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res 68: 10031-10033. doi:10.1158/0008-5472.CAN-08-3010. PubMed: 19074866.
42. Astin JW, Batson J, Kadir S, Charlet J, Persad RA et al. (2010) Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells. Nat Cell Biol 12: 1194-1204. doi:10.1038/ncb2122. PubMed: 21076414.
43. Li G, Ji XD, Gao H, Zhao JS, Xu JF et al. (2012) EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. Nat Commun 3: 667. doi:10.1038/ncomms1675. PubMed: 22314363.
44. Ståhl S, Branca RM, Efazat G, Ruzzene M, Zhivotovsky B et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10: 2566-2578. doi:10.1021/pr200037u. PubMed: 21413766.
45. Noberini R, Rubio de la Torre E, Pasquale EB (2012) Profiling Eph receptor expression in cells and tissues: a targeted mass spectrometry approach. Cell Adh Migr 6: 102-112. doi:10.4161/cam.19620. PubMed: 22568954.
46. Walker-Daniels J, Riese DJ 2nd, Kinch MS (2002) c-Cbl-Dependent EphA2 Protein Degradation Is Induced by Ligand Binding. Mol Cancer Res 1: 79-87. PubMed: 12496371. (Pubitemid 36330213)
47. Mäkinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A et al. (2005) PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 19: 397-410. doi:10.1101/gad.330105. PubMed: 15687262. (Pubitemid 40189302)
48. Salvucci O, Maric D, Economopoulou M, Sakakibara S, Merlin S et al. (2009) EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 114: 1707-1716. doi: 10.1182/blood-2008-12-192294. PubMed: 19411631.
49. Follenzi A, Naldini L (2002) Generation of HIV-1 derived lentiviral vectors. Methods Enzymol 346: 454-465. doi:10.1016/S0076-6879(02)46071-5. PubMed: 11883085. (Pubitemid 41103153)
50. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB (2004) Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A 101: 5583-5588. doi:10.1073/pnas.0401381101. PubMed: 15067119. (Pubitemid 38481199)
51. Holen HL, Zernichow L, Fjelland KE, Evenroed IM, Prydz K et al. (2011) Ephrin-B3 binds to a sulfated cell-surface receptor. Biochem J 433: 215-223. doi:10.1042/BJ20100865. PubMed: 20925654.